Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Waldenstrom's Macroglobulinemia
NCT00003512Phase 2Withdrawn
- Sponsor
- Burzynski Research Institute
- Start
- Feb 1999
- Primary completion
- Apr 2000
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in Waldenstrom macroglobulinemia (WM), sponsored by Burzynski Research Institute. Planned start Feb 1999; status: withdrawn.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00003512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003512.